Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Abstract Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an opportunity to evaluate novel treatment strategies in a person...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kushtrim Kryeziu, Seyed H. Moosavi, Christian H. Bergsland, Marianne G. Guren, Peter W. Eide, Max Z. Totland, Kristoffer Lassen, Andreas Abildgaard, Arild Nesbakken, Anita Sveen, Ragnhild A. Lothe
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2021-09-01
Col·lecció:	Journal of Translational Medicine
Matèries:	Rectal cancer Liver metastasis Patient-derived organoid LCL161
Accés en línia:	https://doi.org/10.1186/s12967-021-03062-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!